Takeda
CD19-CAR-NK (with MD Anderson) — cord-blood, phase II lymphoma.
- Country
- Japan
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsemafdanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Enzymatic therapy for celiac | food-alt-protein | Medium | → |
| NK-cell & CAR-NK therapy | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.